Takeda Pharmaceutical Co Ltd- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Takeda Pharmaceutical Co Ltd 公司

武田药品株式会社是一家日本公司，主要从事药品的研发、制造、销售和许可。公司专注于胃肠道疾病、罕见疾病、血浆衍生物（免疫疾病）、肿瘤学（癌症）和神经科学（神经精神疾病）的主要业务领域。公司专注于三个研发领域：创新生物制药，重点关注胃肠道和炎症疾病、神经科学和肿瘤学，以及血浆衍生物和疫苗。大多数药品用于治疗重点疾病领域和血浆衍生物领域的罕见疾病。公司在日本、美国、欧洲和中国开展业务。

公司简介

公司代码TAK

公司名称Takeda Pharmaceutical Co Ltd

上市日期May 16, 1949

成立日期1925

CEOMr. Christophe Weber

员工数量49281

证券类型Depository Receipt

年结日May 16

公司地址4F

城市CHUO-KU

上市交易所NYSE Consolidated

国家Japan

邮编103-8668

电话81332782111

网址https://www.takeda.com/

公司代码TAK

上市日期May 16, 1949

成立日期1925

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Steven H. (Steve) Gillis, Ph.D.

Independent Director

8.26K

--

Ms. Kimberly A. Reed

Independent Director

1.38K

-85.30%

Mr. Christophe Weber

President, Chief Executive Officer, Representative Director

--

Ms. Emiko Higashi

Independent Director

--

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Ms. Miki Tsusaka

Independent Director

--

Mr. Koji Hatsukawa

Independent Director

--

Mr. Milano Furuta

Chief Financial Officer, Director

--

Mr. Masami Iijima

Chairman of Board of Directors, Independent Director

--

Dr. Andrew S. Plump, Ph.D.

President of Research & Development, Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Steven H. (Steve) Gillis, Ph.D.

Independent Director

8.26K

--

Ms. Kimberly A. Reed

Independent Director

1.38K

-85.30%

Mr. Christophe Weber

President, Chief Executive Officer, Representative Director

--

Ms. Emiko Higashi

Independent Director

--

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Ms. Miki Tsusaka

Independent Director

--

收入明细

单位: JPY更新时间: 4月6日周日

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2021

FY2020

FY2019

业务JPY

名称

营收

占比

Gastrointestinal diseases

344.12B

30.08%

Plasma derivatives

248.54B

21.72%

Rare diseases

190.32B

16.63%

Oncology

143.10B

12.51%

Neuroscience

141.94B

12.41%

Other

76.15B

6.66%

地区JPY

名称

营收

占比

United States

593.84B

51.90%

Europe And Canada (Country)

262.60B

22.95%

Japan

108.34B

9.47%

Asia

69.19B

6.05%

Latin America

58.66B

5.13%

Other

51.53B

4.50%

业务

地区

业务JPY

名称

营收

占比

Gastrointestinal diseases

344.12B

30.08%

Plasma derivatives

248.54B

21.72%

Rare diseases

190.32B

16.63%

Oncology

143.10B

12.51%

Neuroscience

141.94B

12.41%

Other

76.15B

6.66%

股东统计

更新时间: 4月8日周二

持股股东

股东类型

持股股东

股东统计

占比

Capital Research Global Investors

0.42%

Parametric Portfolio Associates LLC

0.16%

Arrowstreet Capital, Limited Partnership

0.14%

Fidelity Management & Research Company LLC

0.11%

First Trust Advisors L.P.

0.10%

Other

99.07%

持股股东

股东统计

占比

Capital Research Global Investors

0.42%

Parametric Portfolio Associates LLC

0.16%

Arrowstreet Capital, Limited Partnership

0.14%

Fidelity Management & Research Company LLC

0.11%

First Trust Advisors L.P.

0.10%

Other

99.07%

股东类型

股东统计

占比

Investment Advisor

1.55%

Investment Advisor/Hedge Fund

0.35%

Hedge Fund

0.27%

Research Firm

0.14%

Family Office

0.01%

Family Office

0.01%

Family Office

0.01%

Other

97.64%

机构持股

更新时间: 1月19日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q1

574

73.02M

2.32%

-10.12M

2024Q4

595

73.56M

2.33%

-9.88M

2024Q3

583

77.60M

2.45%

-3.33M

2024Q2

581

73.43M

2.34%

-14.54M

2024Q1

593

78.98M

2.52%

-11.62M

2023Q4

609

83.80M

2.67%

-18.91M

2023Q3

621

81.24M

2.59%

-37.59M

2023Q2

617

84.64M

2.72%

-34.14M

2023Q1

627

84.81M

2.73%

-21.74M

2022Q4

637

69.93M

2.25%

-40.01M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Capital Research Global Investors

13.16M

0.42%

+25.31K

+0.19%

Dec 31, 2024

Parametric Portfolio Associates LLC

5.14M

0.16%

+961.51K

+23.02%

Dec 31, 2024

Arrowstreet Capital, Limited Partnership

4.22M

0.13%

-419.02K

-9.04%

Dec 31, 2024

Fidelity Management & Research Company LLC

3.33M

0.11%

+438.69K

+15.18%

Dec 31, 2024

First Trust Advisors L.P.

3.24M

0.1%

+62.72K

+1.97%

Dec 31, 2024

Renaissance Technologies LLC

3.08M

0.1%

-139.40K

-4.33%

Dec 31, 2024

Brandes Investment Partners, L.P.

3.04M

0.1%

-192.02K

-5.94%

Dec 31, 2024

Goldman Sachs Asset Management, L.P.

2.32M

0.07%

+131.24K

+6.01%

Dec 31, 2024

Van Eck Associates Corporation

2.21M

0.07%

+35.19K

+1.62%

Dec 31, 2024

Aperio Group, LLC

2.20M

0.07%

+313.03K

+16.56%

Dec 31, 2024

持股ETF

更新时间: 4月6日周日

机构名称

占比

VanEck Pharmaceutical ETF

4.7%

SGI Enhanced Global Income ETF

3.05%

Roundhill GLP-1 & Weight Loss ETF

2.1%

ActivePassive International Equity ETF

0.6%

First Trust Value Line Dividend Index Fund

0.45%

Pacer Trendpilot International ETF

0.26%

Avantis International Equity ETF

0.07%

Avantis Responsible International Equity ETF

0.07%

DFA Dimensional International Core Equity 2 ETF

0%

Pacer Developed Markets International Cash Cws 100

0%

VanEck Pharmaceutical ETF

占比4.7%

SGI Enhanced Global Income ETF

占比3.05%

Roundhill GLP-1 & Weight Loss ETF

占比2.1%

ActivePassive International Equity ETF

占比0.6%

First Trust Value Line Dividend Index Fund

占比0.45%

Pacer Trendpilot International ETF

占比0.26%

Avantis International Equity ETF

占比0.07%

Avantis Responsible International Equity ETF

占比0.07%

DFA Dimensional International Core Equity 2 ETF

占比0%

Pacer Developed Markets International Cash Cws 100

占比0%

分红派息

近5年累计派现 1.42T 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Sep 12, 2024

TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024

Sep 30, 2024

Dec 12, 2024

Sep 30, 2024

Mar 14, 2024

TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024

Mar 28, 2024

Jul 08, 2024

Mar 27, 2024

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Takeda Pharmaceutical Co Ltd

15.025USD

Takeda Pharmaceutical Co Ltd

15.025

概览

公司